{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:45:37Z","timestamp":1790214337897,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.pcad.2012.05.003","type":"journal-article","created":{"date-parts":[[2012,6,9]],"date-time":"2012-06-09T02:16:57Z","timestamp":1339208217000},"page":"535-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Can Pharmacologic Gradient Reduction Decrease Mortality in Hypertrophic Cardiomyopathy?"],"prefix":"10.1016","volume":"54","author":[{"given":"Dan","family":"Musat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silviana","family":"Marineci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark V.","family":"Sherrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2012.05.003_bb0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.05.003_bb0010","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1161\/01.CIR.102.8.858","article-title":"Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population","volume":"102","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.05.003_bb0015","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0020","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/eurheartj\/ehq308","article-title":"Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up","volume":"31","author":"Dimitrow","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2012.05.003_bb0025","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","article-title":"Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy","volume":"342","author":"Spirito","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2012.05.003_bb0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(00)04005-8","article-title":"Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy","volume":"357","author":"Elliott","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2012.05.003_bb0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0025-6196(11)60890-2","article-title":"Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy","volume":"83","author":"Olivotto","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pcad.2012.05.003_bb0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacc.2008.11.069","volume":"54","author":"Maron","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0045","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/hrt.2008.154435","article-title":"Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future","volume":"94","author":"Ommen","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2012.05.003_bb0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2012.05.003_bb0055","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1093\/eurheartj\/ehl383","article-title":"Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2012.05.003_bb0060","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.05.003_bb0065","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.108.781401","article-title":"Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy","volume":"118","author":"Maron","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.05.003_bb0070","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2012.05.003_bb0075","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2004.12.067","article-title":"The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms","volume":"45","author":"Autore","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2009.01.079","article-title":"Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study","volume":"54","author":"Sorajja","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0085","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/01.CIR.79.4.766","article-title":"Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy","volume":"79","author":"Cannon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.05.003_bb0090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0894-7317(97)70112-3","article-title":"Mid-systolic drop in left ventricular ejection velocity in obstructive hypertrophic cardiomyopathy\u2013the lobster claw abnormality","volume":"10","author":"Sherrid","year":"1997","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2012.05.003_bb0095","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1540-8175.2009.00905.x","article-title":"Severe symptoms in mid and apical hypertrophic cardiomyopathy","volume":"26","author":"Shah","year":"2009","journal-title":"Echocardiography"},{"key":"10.1016\/j.pcad.2012.05.003_bb0100","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.jacc.2011.02.033","article-title":"Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy","volume":"57","author":"Minami","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0105","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/hrt.2006.099416","article-title":"Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy","volume":"93","author":"Melacini","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2012.05.003_bb0110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0115","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/eurheartj\/ehm117","article-title":"Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy","volume":"28","author":"McLeod","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2012.05.003_bb0120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/CIRCHEARTFAILURE.109.862359","article-title":"Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution","volume":"3","author":"ten Cate","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2012.05.003_bb0125","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.38.5.846","article-title":"Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol","volume":"38","author":"Flamm","year":"1968","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.05.003_bb0130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijcard.2006.04.080","article-title":"Beta-blocker therapy for dynamic left ventricular outflow tract obstruction induced by exercise","volume":"117","author":"Cabrera-Bueno","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0002-9149(73)90012-X","article-title":"Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy","volume":"31","author":"Stenson","year":"1973","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pcad.2006.08.001","article-title":"Pathophysiology and treatment of hypertrophic cardiomyopathy","volume":"49","author":"Sherrid","year":"2006","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2012.05.003_bb0145","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.amjcard.2010.06.059","article-title":"Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline","volume":"106","author":"Kajimoto","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0150","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.64.3.437","article-title":"Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy","volume":"64","author":"Epstein","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2012.05.003_bb0155","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0160","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0735-1097(87)80207-3","article-title":"Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect","volume":"10","author":"Teichman","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2012.05.003_bb0165","first-page":"A18632","article-title":"Stepped management of obstructive hypertrophic cardiomyopathy in patients refractory to bete-blockade","volume":"122","author":"Sherrid","year":"2010","journal-title":"Circulation"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062012000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062012000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:15:01Z","timestamp":1758500101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062012000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0033062012000552"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2012.05.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can Pharmacologic Gradient Reduction Decrease Mortality in Hypertrophic Cardiomyopathy?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2012.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}